Skip to main content

XDx, LabCorp Team up on Lupus Dx Development

NEW YORK (GenomeWeb News) – XDx today announced a deal with Laboratory Corporation of America to develop and commercialize a diagnostic test for systemic lupus erythematosus (SLE).

The two firms will work together in the discovery phase while LabCorp will develop and commercialize a test to predict flares of lupus. The collaboration pairs XDx's autoimmune diagnostics research and discovery expertise as well as SLE blood sample database with LabCorp's diagnostic development and commercialization resources, they said.

Financial and other terms of the deal were not disclosed.

Pierre Cassigneul, president and CEO of Brisbane, Calif.-based XDx, said the deal builds on the success of the company's AlloMap gene expression test for monitoring heart transplant rejection, and the firm is now concentrating on expanding its pipeline to include diagnostic tests directed at the immune system.

Mark Brecher, chief medical officer for LabCorp, added, "This agreement with XDx advances our strategy of developing and introducing tests to provide personalized information that can be used to help physicians and their patients."

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.